Vanguard Group Inc. Buys 845,922 Shares of Kymera Therapeutics, Inc. $KYMR

Vanguard Group Inc. lifted its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 15.6% during the 4th quarter, HoldingsChannel.com reports. The firm owned 6,267,644 shares of the company’s stock after buying an additional 845,922 shares during the period. Vanguard Group Inc. owned approximately 0.09% of Kymera Therapeutics worth $487,685,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of KYMR. US Bancorp DE lifted its position in Kymera Therapeutics by 9.8% during the third quarter. US Bancorp DE now owns 1,865 shares of the company’s stock worth $106,000 after purchasing an additional 166 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in Kymera Therapeutics by 9.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,764 shares of the company’s stock valued at $156,000 after buying an additional 248 shares during the period. Larson Financial Group LLC increased its holdings in Kymera Therapeutics by 81.5% in the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after buying an additional 349 shares during the period. Harbor Capital Advisors Inc. raised its position in shares of Kymera Therapeutics by 2.2% in the 4th quarter. Harbor Capital Advisors Inc. now owns 30,573 shares of the company’s stock valued at $2,379,000 after buying an additional 645 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Kymera Therapeutics by 5.3% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 15,631 shares of the company’s stock valued at $1,216,000 after buying an additional 789 shares in the last quarter.

Trending Headlines about Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Kymera presented new preclinical data showing KT‑579 (oral IRF5 degrader) produced activity comparable or superior to approved/clinically active therapies in IBD models — a meaningful R&D positive if confirmed in clinical studies. Article Title
• Positive Sentiment: Management will participate in multiple May investor conferences (fireside chats), increasing visibility with investors and analysts — typically supportive for sentiment and liquidity. Article Title
• Positive Sentiment: Q1 results and the accompanying presentation prompted analysts to lift estimates in some reports and coverage; positive analyst reaction to quarterly revenue and beats can support the stock. Article Title
• Neutral Sentiment: Kymera published its Q1 earnings presentation (details on pipeline progress, financials and guidance assumptions), useful for investors but not an immediate catalyst by itself. Article Title
• Neutral Sentiment: Company celebrated its 10‑year anniversary and rang the Nasdaq opening bell — PR/branding event with limited direct impact on valuation. Article Title
• Negative Sentiment: Brookline Capital Markets issued multiple model changes: they raised some near‑ and long‑term estimates (e.g., FY2026, FY2028–FY2030) but lowered Q3/Q4 2026 and FY2027 forecasts — the mixed/downgrade elements could weigh on sentiment by signaling slower expected progress or higher near‑term spend. Article Title

Wall Street Analyst Weigh In

KYMR has been the topic of several analyst reports. Canaccord Genuity Group initiated coverage on shares of Kymera Therapeutics in a research report on Wednesday. They set a “buy” rating and a $106.00 price target on the stock. Jefferies Financial Group assumed coverage on shares of Kymera Therapeutics in a research report on Monday, March 16th. They set a “buy” rating and a $110.00 price objective for the company. Piper Sandler raised their target price on Kymera Therapeutics from $125.00 to $140.00 and gave the company an “overweight” rating in a report on Thursday, February 26th. Citigroup lifted their price target on Kymera Therapeutics from $110.00 to $120.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $108.00 price target on shares of Kymera Therapeutics in a report on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $118.10.

Insider Buying and Selling

In other Kymera Therapeutics news, Director Bruce Booth sold 81,866 shares of the company’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $90.13, for a total value of $7,378,582.58. Following the completion of the transaction, the director owned 675,341 shares of the company’s stock, valued at $60,868,484.33. This represents a 10.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Jeremy G. Chadwick sold 91,250 shares of Kymera Therapeutics stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $77.41, for a total value of $7,063,662.50. Following the sale, the chief operating officer directly owned 61,202 shares in the company, valued at $4,737,646.82. The trade was a 59.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 380,734 shares of company stock worth $32,193,902 in the last ninety days. Insiders own 16.01% of the company’s stock.

Kymera Therapeutics Price Performance

KYMR stock opened at $82.71 on Wednesday. The stock has a market cap of $6.80 billion, a price-to-earnings ratio of -23.17 and a beta of 2.06. The company has a 50 day simple moving average of $84.42 and a 200 day simple moving average of $76.61. Kymera Therapeutics, Inc. has a 1 year low of $28.06 and a 1 year high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.18. The firm had revenue of $34.37 million for the quarter, compared to analyst estimates of $8.27 million. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The company’s quarterly revenue was up 55.5% on a year-over-year basis. During the same quarter last year, the business posted ($0.82) earnings per share. On average, equities research analysts anticipate that Kymera Therapeutics, Inc. will post -3.35 EPS for the current fiscal year.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.